EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma

Abstract Both EZH2 and its homolog EZH1 function as histone H3 Lysine 27 (H3K27) methyltransferases and repress the transcription of target genes. Dysregulation of H3K27 trimethylation (H3K27me3) plays an important role in the development and progression of cancers such as hepatocellular carcinoma (...

Full description

Bibliographic Details
Main Authors: Yuko Kusakabe, Tetsuhiro Chiba, Motohiko Oshima, Shuhei Koide, Ola Rizq, Kazumasa Aoyama, Junjie Ao, Tatsuya Kaneko, Hiroaki Kanzaki, Kengo Kanayama, Takahiro Maeda, Tomoko Saito, Ryo Nakagawa, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Sadahisa Ogasawara, Eiichiro Suzuki, Shingo Nakamoto, Shin Yasui, Rintaro Mikata, Ryosuke Muroyama, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Naoya Mimura, Anqi Ma, Jian Jin, Yoh Zen, Masayuki Otsuka, Atsushi Kaneda, Atsushi Iwama, Naoya Kato
Format: Article
Language:English
Published: Nature Portfolio 2021-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-00889-0

Internet

https://doi.org/10.1038/s41598-021-00889-0

Similar Items